Ask a research question about Hypertensive Heart Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Hypertensive Heart Disease
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-02-17T21:53:14Z'
category: Cardiovascular
parents:
- Hypertension
- Heart Disease
has_subtypes:
- name: Left Ventricular Hypertrophy
description: Thickening of the heart's main pumping chamber (left ventricle)
in response to high blood pressure.
evidence:
- reference: PMID:16097361
reference_title: "Hypertensive heart disease."
supports: PARTIAL
snippet: Left ventricular hypertrophy (LVH) and diastolic dysfunction
(CHF-D) are the early manifestations of cardiovascular target organ damage
in patients with arterial hypertension and signify hypertensive heart
disease.
explanation: The reference indicates that left ventricular hypertrophy (LVH)
is a manifestation of hypertensive heart disease, but it does not
explicitly state that LVH is a subtype of hypertensive heart disease.
However, since it implies a direct relationship, partial support is
inferred.
- name: Coronary Artery Disease
description: Narrowing of the blood vessels that supply the heart, worsened by
hypertension.
evidence:
- reference: PMID:37739329
reference_title: "Hypertension, coronary artery disease and myocardial ischemic syndromes."
supports: SUPPORT
snippet: Hypertension represents a major contributor to the development of
coronary artery disease. The pathophysiological mechanisms underlying the
link between hypertension and CAD are complex and include overactivation
of neurohormones, accelerated development of the atherosclerotic plaque,
endothelial dysfunction, altered intramyocardial coronary circulation,
hypertension-mediated cardiac and vascular damage and the relationship
between arterial stiffness and coronary perfusion.
explanation: The literature explicitly mentions the contribution of
hypertension to the development of coronary artery disease, which involves
narrowing of the blood vessels that supply the heart.
- name: Heart Failure
description: Weakening of the heart muscle, leading to reduced pumping
efficiency, often as a result of long-standing hypertension.
evidence:
- reference: PMID:31472888
reference_title: "Hypertension and Heart Failure."
supports: SUPPORT
snippet: Hypertensive heart disease represents a spectrum of illnesses from
uncontrolled hypertension to heart failure.
explanation: The abstract indicates that heart failure can develop as part
of hypertensive heart disease.
- reference: PMID:36030347
reference_title: "Sex, gender, and subclinical hypertensiveorgan damage-heart."
supports: SUPPORT
snippet: Current evidence, based on cross-sectional and longitudinal
observational studies as well as real-world registries and randomized
controlled trials, suggests that women are more at risk of developing (and
maintaining) LVH, concentric remodeling and subclinical LV dysfunction,
namely the morpho-functional features of heart failure with preserved
ejection fraction.
explanation: The study supports the presence of heart failure as an outcome
of hypertensive heart disease.
- reference: PMID:35679365
reference_title: "Large and Small Animal Models of Heart Failure With Reduced Ejection Fraction."
supports: SUPPORT
snippet: Several factors chronically lead to HF, including cardiac volume
and pressure overload that may result from hypertension.
explanation: Heart failure as a result of hypertension is explicitly
mentioned.
- reference: PMID:27884237
reference_title: "Diastolic Dysfunction and Hypertension."
supports: SUPPORT
snippet: Left ventricular (LV) diastolic dysfunction (LVDD) is characterized
by alterations in LV diastolic filling, and is a strong predictor of
cardiovascular events and heart failure. Hypertension is the most
important risk factor for LVDD in the community and promotes LVDD through
several mechanisms.
explanation: Hypertension leading to heart failure is supported via the
mechanism of LV diastolic dysfunction.
prevalence:
- population: Adults over 50
percentage: 10-20
evidence:
- reference: PMID:35372212
reference_title: "Trends in the Prevalence of Hypertensive Heart Disease in China From 1990 to 2019: A Joinpoint and Age-Period-Cohort Analysis."
supports: REFUTE
snippet: From 1990 to 2019, HHD prevalence in China showed decreasing trends
in both sexes combined... but significant increases in the age groups of
15-19, 20-24, ..., and 60-64 years.
explanation: The study noted significant increasing trends in HHD prevalence
in specific age groups, including older adults, but it did not provide
specific percentage values within the 10-20 range for adults over 50.
Instead, it indicates general trends rather than precise prevalence rates.
- reference: PMID:9256850
reference_title: "Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults."
supports: NO_EVIDENCE
snippet: 'CONCLUSIONS: Congestive heart failure is a major public health problem
in the United States today as a result of its high and increasing prevalence
in the older population...'
explanation: The reference discusses the prevalence and impact of congestive
heart failure in older adults but does not offer specific statistics on
the overall prevalence rate of hypertensive heart disease in the 10-20%
range for adults over 50.
progression:
- phase: Asymptomatic
age_range: 40-60
evidence:
- reference: PMID:38596912
reference_title: "Stage B Heart Failure Is Ubiquitous in Emergency Patients with Asymptomatic Hypertension."
supports: SUPPORT
snippet: This study documents the point prevalence of subclinical heart
disease in emergency patients with asymptomatic hypertension.
explanation: This reference supports the statement for the asymptomatic
phase by documenting the presence of subclinical heart disease in patients
with asymptomatic hypertension, which aligns with the concept of
progression in hypertensive heart disease, but it does not focus
specifically on the age range of 40-60.
- phase: Symptomatic
age_range: 50-80
evidence:
- reference: PMID:21263005
reference_title: "The progression of hypertensive heart disease."
supports: PARTIAL
snippet: The progression of hypertensive heart disease.
explanation: The reference discusses the progression of hypertensive heart
disease but does not specify the age range of 50-80 or the phase as
symptomatic.
- reference: PMID:38596912
reference_title: "Stage B Heart Failure Is Ubiquitous in Emergency Patients with Asymptomatic Hypertension."
supports: NO_EVIDENCE
snippet: Black, Hispanic, and female patients with asymptomatic hypertension
are on the continuum for developing overt heart failure.
explanation: The study focuses on the prevalence of subclinical heart
disease in asymptomatic hypertensive patients, without specifying the age
range of 50-80 or mentioning symptomatic progression.
- reference: PMID:37698022
reference_title: "Global, regional, and national burden of hypertensive heart disease among older adults in 204 countries and territories between 1990 and 2019: a trend analysis."
supports: PARTIAL
snippet: In the past three decades, there has been an overall increasing
trend in the prevalence of HHD among older adults worldwide.
explanation: While the reference provides data about the prevalence and
burden of hypertensive heart disease among older adults, it does not
specifically address the symptomatic progression of the disease.
- reference: PMID:34809918
reference_title: "Left Heart Disease-Related Pulmonary Hypertension."
supports: SUPPORT
snippet: Pulmonary hypertension (PH) due to left heart disease (LHD; group 2
PH) is a common complication of heart failure.
explanation: The reference describes pulmonary hypertension due to left
heart disease as a progression related to heart failure, which fits the
description of symptomatic progression within the age range.
- reference: PMID:35138872
reference_title: "Hypertension-Mediated Organ Damage: Prevalence, Correlates, and Prognosis in the Community."
supports: NO_EVIDENCE
snippet: The presence of HMOD confers incremental prognostic information
regarding cardiovascular disease risk at every BP category.
explanation: The study emphasizes the presence and prognosis of
hypertension-mediated organ damage but does not detail the progression of
hypertensive heart disease specifically within the 50-80 age range or the
symptomatic phase.
pathophysiology:
- name: Increased Cardiac Workload
description: Hypertension increases the pressure the heart must pump against,
leading to cardiac remodeling and dysfunction over time.
evidence:
- reference: PMID:38428029
reference_title: "Large animal models of pressure overload-induced cardiac left ventricular hypertrophy to study remodelling of the human heart with aortic stenosis."
supports: SUPPORT
snippet: Pathologic cardiac hypertrophy is a common consequence of many
cardiovascular diseases, including aortic stenosis (AS). AS is known to
increase the pressure load of the left ventricle, causing a compensative
response of the cardiac muscle, which progressively will lead to dilation
and heart failure.
explanation: This reference discusses the pressure load on the left
ventricle due to aortic stenosis, leading to cardiac remodeling and
dysfunction, supporting the described mechanism of hypertensive heart
disease.
- reference: PMID:7496052
reference_title: "Hypertensive heart disease and heart failure."
supports: SUPPORT
snippet: Hypertension is associated with the remodeling of left ventricular
geometry and abnormalities of function that may precede geometric changes.
Rather than a specific disease, 'hypertensive heart failure' is a spectrum
of disorders that result from left ventricular geometric changes and
comorbid conditions.
explanation: The reference explains the remodeling of the left ventricle due
to hypertension and the functional abnormalities that occur, supporting
the described mechanism of hypertensive heart disease.
- reference: PMID:19427497
reference_title: "Diastolic dysfunction as a link between hypertension and heart failure."
supports: SUPPORT
snippet: LVDD as an early measure of myocardial end-organ damage is commonly
associated with hypertension and may well precede development of LVH in
hypertension.
explanation: This reference discusses the association between hypertension
and left ventricular dysfunction, an early indicator of cardiac remodeling
and dysfunction, supporting the described mechanism.
- reference: PMID:28082430
reference_title: "Increased cardiac work provides a link between systemic hypertension and heart failure."
supports: SUPPORT
snippet: SHR had lower ejection fraction compared with WKY at all ages, but
there was no difference in cardiac output at any age. At 21 month the SHR
had significantly elevated stroke work (51 +/- 3 mL.mmHg SHR vs. 24 +/- 2
mL.mmHg WKY; n = 8, 4; P < 0.001) and cardiac minute work (14.2 +/- 1.2
L.mmHg/min SHR vs. 6.2 +/- 0.8 L.mmHg/min WKY; n = 8, 4; P < 0.001)
compared to control, in addition to significantly larger left ventricular
mass to body mass ratio (3.61 +/- 0.15 mg/g SHR vs. 2.11 +/- 0.008 mg/g
WKY; n = 8, 6; P < 0.001).
explanation: This study in spontaneously hypertensive rats shows increased
cardiac work and hypertrophy, which aligns with the described mechanism of
increased cardiac workload leading to dysfunction.
- name: Left Ventricular Hypertrophy
description: The heart muscle thickens to cope with increased workload, but
this can lead to stiffness and impaired filling.
cell_types:
- preferred_term: Cardiomyocyte
term:
id: CL:0000746
label: cardiac muscle cell
evidence:
- reference: PMID:11062603
reference_title: "Hypertension and the heart."
supports: SUPPORT
snippet: 'Sustained increase in arterial pressure causes left ventricular hypertrophy
and adversely affects all myocardial compartments: myocytes, interstitium, and
coronary vasculature.'
explanation: The paper discusses how hypertension causes left ventricular
hypertrophy and affects multiple myocardial compartments.
- reference: PMID:36933415
reference_title: "Cardiac hypertrophy simulations using parametric and echocardiography-based left ventricle model with shell finite elements."
supports: SUPPORT
snippet: We computed both eccentric and concentric hypertrophy effects and
tracked changes in the ventricle shape and wall thickness.
explanation: The study confirms that changes in wall thickness and
ventricular shape due to hypertrophy reflect an adaptation to increased
workload.
- reference: PMID:10652906
reference_title: "Hypertensive heart disease."
supports: SUPPORT
snippet: Left ventricular hypertrophy (LVH) is pathognomonic of HHD.
explanation: Left ventricular hypertrophy is directly associated with
hypertensive heart disease and involves thickening of the heart muscle.
- reference: PMID:37827810
reference_title: "Antagonism of contractile forces in left ventricular hypertrophy: a diagnostic challenge for better pathophysiological and clinical understanding."
supports: SUPPORT
snippet: In case of hypertrophy, an increased influence of the dilating
transmural fibre component might counteract systolic wall thickening,
thereby counteract cardiac output.
explanation: The reference discusses the influence of hypertrophy on wall
thickening and heart function.
- name: Myocardial Ischemia
description: Hypertension can worsen atherosclerosis in the coronary arteries,
reducing blood flow to the heart muscle.
evidence:
- reference: PMID:37739329
reference_title: "Hypertension, coronary artery disease and myocardial ischemic syndromes."
supports: SUPPORT
snippet: Hypertension represents a major contributor to the development of
coronary artery disease. The pathophysiological mechanisms underlying the
link between hypertension and CAD are complex and include overactivation
of neurohormones, accelerated development of the atherosclerotic plaque,
endothelial dysfunction, altered intramyocardial coronary circulation...
explanation: This reference outlines how hypertension can lead to coronary
artery disease by affecting atherosclerotic plaque development,
endothelial dysfunction, and coronary circulation, which are consistent
with the statement.
- reference: PMID:11062603
reference_title: "Hypertension and the heart."
supports: SUPPORT
snippet: 'Sustained increase in arterial pressure causes left ventricular hypertrophy
and adversely affects all myocardial compartments: myocytes, interstitium, and
coronary vasculature. Ventricular hypertrophy significantly increases the risk
for cardiovascular morbidity and mortality in hypertensive disease. Impairments
in coronary circulation and ventricular fibrosis, which are an essential part
of hypertensive disease...'
explanation: The report discusses the negative impact of hypertension on
coronary circulation and the involvement of coronary vasculature
impairments due to hypertensive disease, supporting the statement.
- reference: PMID:33143256
reference_title: "Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction."
supports: SUPPORT
snippet: Ischemic heart disease still represents a large burden on
individuals and health care resources worldwide. By conventions, it is
equated with atherosclerotic plaque due to flow-limiting obstruction in
large-medium sized coronary arteries. However, clinical, angiographic and
autoptic findings suggest a multifaceted pathophysiology for ischemic
heart disease and just some cases are caused by severe or complicated
atherosclerotic plaques.
explanation: This reference explains that ischemic heart disease, which can
result from severe atherosclerotic plaques, aligns with the statement that
hypertension-induced atherosclerosis can reduce coronary blood flow,
contributing to myocardial ischemia.
- name: Cardiac Fibrosis
description: Chronic pressure overload stimulates fibroblasts to deposit
excess collagen in the heart, stiffening it. TGF-β/SMAD signaling drives
fibroblast-to-myofibroblast transition and increased collagen deposition.
cell_types:
- preferred_term: Cardiac Fibroblast
term:
id: CL:0002548
label: fibroblast of cardiac tissue
biological_processes:
- preferred_term: extracellular matrix organization
term:
id: GO:0030198
label: extracellular matrix organization
- preferred_term: collagen fibril organization
term:
id: GO:0030199
label: collagen fibril organization
locations:
- preferred_term: myocardial interstitium
- preferred_term: perivascular space
evidence:
- reference: PMID:37999643
reference_title: "Fibroblasts under pressure: cardiac fibroblast responses to hypertension and antihypertensive therapies."
supports: SUPPORT
snippet: In response to increased peripheral resistance in hypertension,
intensified mechanical stretch in the myocardium induces cardiomyocyte
hypertrophy and fibroblast activation to withstand increased pressure
overload. This changes the structure and function of the heart, leading to
pathological cardiac remodeling and eventual progression to heart failure.
explanation: The activation of fibroblasts in response to hypertension and
their role in cardiac remodeling aligns with the statement that chronic
pressure overload stimulates fibroblasts to deposit excess collagen in the
heart.
- reference: PMID:33568808
reference_title: "Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches."
supports: SUPPORT
snippet: Diffuse myocardial fibrosis resulting from the excessive deposition
of collagen fibres through the entire myocardium is encountered in a
number of chronic cardiac diseases. This lesion results from alterations
in the regulation of fibrillary collagen turnover by fibroblasts,
facilitating the excessive deposition of type I and type III collagen
fibres within the myocardial interstitium and around intramyocardial
vessels.
explanation: This reference details how fibroblasts facilitate excessive
collagen deposition in the myocardium, which supports the statement
regarding cardiac fibrosis due to chronic pressure overload.
- reference: PMID:2532916
reference_title: "Myocardial collagen remodeling in pressure overload hypertrophy. A case for interstitial heart disease."
supports: SUPPORT
snippet: In left ventricular pressure overload a reactive interstitial
fibrosis, having distinctive biochemical and structural features, is seen.
This reactive fibrosis occurs in the absence of myocyte necrosis, is
progressive in nature, and initially is an adaptive response that
preserves the force generating capacity, or active (systolic) stiffness,
of the hypertrophied myocardium.
explanation: The description of reactive interstitial fibrosis in response
to pressure overload supports the statement about fibroblasts depositing
excess collagen in the heart under chronic pressure overload conditions,
leading to fibrosis and stiffening.
- reference: PMID:10829097
reference_title: "Ischemia and fibrosis: the risk mechanisms of hypertensive heart disease."
supports: SUPPORT
snippet: Mechanisms underlying risk associated with hypertensive heart
disease (HHD) and left ventricular hypertrophy (LVH) are discussed in this
report and provide a rationale for understanding this very common and
important cause of death from hypertension and its complications.
Emphasized are impaired coronary hemodynamics, endothelial dysfunction,
and ventricular fibrosis from increased collagen deposition intramurally
and perivascularly.
explanation: The mention of ventricular fibrosis due to increased collagen
deposition supports the statement that chronic pressure overload results
in fibroblasts depositing excess collagen, leading to cardiac fibrosis.
- reference: PMID:33570899
reference_title: "T helper 17 cell responses induce cardiac hypertrophy and remodeling in essential hypertension."
supports: SUPPORT
snippet: The differentiation of TH17 cells reflected the cardiac hypertrophy
and remodeling response to hypertension-induced pressure overload, and it
might be a potential inflammatory marker to predict the prognosis of
hypertensive patients.
explanation: Although this snippet primarily focuses on TH17 cells, it
indicates that remodeling due to hypertension includes elements of
fibroblast activation and fibrosis.
- name: Coronary Microvascular Dysfunction
description: Hypertension causes endothelial dysfunction, microvascular
rarefaction, and perivascular fibrosis in the coronary microvasculature,
reducing coronary flow reserve and oxygen delivery to the hypertrophied
myocardium. This contributes to ischemia and progression to heart failure
with preserved ejection fraction.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
- preferred_term: pericyte
term:
id: CL:0000669
label: pericyte
biological_processes:
- preferred_term: angiogenesis
term:
id: GO:0001525
label: angiogenesis
- preferred_term: regulation of nitric oxide biosynthetic process
term:
id: GO:0045428
label: regulation of nitric oxide biosynthetic process
locations:
- preferred_term: coronary microvasculature
notes: Pericyte loss and endothelial dysfunction lead to capillary
rarefaction, which is a hallmark of hypertensive heart disease progression
to HFpEF
- name: Oxidative Stress and Mitochondrial Dysfunction
description: NADPH oxidases (NOX2 and NOX4) generate reactive oxygen species
in response to mechanical stress and Ang II signaling. This oxidative stress
damages mitochondria, reduces ATP production, and activates pro-fibrotic
signaling pathways including NF-κB.
biological_processes:
- preferred_term: response to oxidative stress
term:
id: GO:0006979
label: response to oxidative stress
- preferred_term: superoxide metabolic process
term:
id: GO:0006801
label: superoxide metabolic process
- preferred_term: mitochondrial electron transport
term:
id: GO:0006120
label: mitochondrial electron transport, NADH to ubiquinone
cellular_components:
- preferred_term: mitochondrion
term:
id: GO:0005739
label: mitochondrion
notes: NOX2 (CYBB gene) and NOX4 are major enzymatic ROS sources linking
mechanical and Ang II stimuli to oxidative damage
- name: Inflammasome Activation
description: Pressure overload and oxidative stress activate the NLRP3
inflammasome, leading to caspase-1 activation and release of IL-1β and
IL-18. This inflammatory signaling amplifies cardiac fibrosis, hypertrophy,
and adverse remodeling.
biological_processes:
- preferred_term: interleukin-1 beta production
term:
id: GO:0032611
label: interleukin-1 beta production
cellular_components:
- preferred_term: canonical inflammasome complex
term:
id: GO:0061702
label: canonical inflammasome complex
notes: NLRP3 inflammasome activation promotes pyroptosis and chronic
inflammation in hypertensive heart disease
phenotypes:
- category: Cardiovascular
name: Dyspnea
frequency: FREQUENT
sequelae:
- target: Reduced Exercise Tolerance
- target: Heart Failure Exacerbations
evidence:
- reference: PMID:31472880
reference_title: "The Evolution from Hypertension to Heart Failure."
supports: PARTIAL
snippet: Hypertensive heart disease includes the development of diastolic
dysfunction, left ventricular hypertrophy, and heart failure with
preserved and reduced ejection fraction. The development of heart failure
can occur because of complications of ischemic heart disease or from
progression of diastolic dysfunction to heart failure with preserved
ejection fraction degenerating to a dilated heart with systolic
dysfunction or heart failure with reduced ejection fraction.
explanation: The reference mentions heart failure as a frequent complication
of hypertensive heart disease, but it does not specifically address
dyspnea.
- reference: PMID:15950133
reference_title: "Dyspnea and leg effort during exercise."
supports: PARTIAL
snippet: Dyspnea and leg effort are the major symptoms limiting exercise in
healthy subjects and in patients with a variety of respiratory disorders.
explanation: While the reference discusses dyspnea as a symptom that limits
exercise tolerance, it is not specific to hypertensive heart disease.
- reference: PMID:37345800
reference_title: "Ventilatory Efficiency Is Reduced in People With Hypertension During Exercise."
supports: SUPPORT
snippet: Ventilatory efficiency is impaired people with hypertension without
a diagnosis of heart failure versus normotensive individuals.
explanation: This reference implies that dyspnea could be an issue in
hypertensive patients, which could lead to reduced exercise tolerance.
- reference: PMID:26569571
reference_title: "Exercise Training in Group 2 Pulmonary Hypertension: Which Intensity and What Modality."
supports: PARTIAL
snippet: Pulmonary hypertension (PH) due to left-sided heart disease (LSHD)
is a common and disconcerting occurrence. For example, both heart failure
(HF) with preserved and reduced ejection fraction (HFpEF and HFrEF) often
lead to PH as a consequence of a chronic elevation in left atrial filling
pressure.
explanation: It mentions heart failure and its link to dyspnea indirectly
through pulmonary hypertension but does not focus on hypertensive heart
disease specifically.
phenotype_term:
preferred_term: Dyspnea
term:
id: HP:0002094
label: Dyspnea
- category: Cardiovascular
name: Chest Pain
frequency: OCCASIONAL
notes: May indicate underlying coronary artery disease
evidence:
- reference: PMID:35061769
reference_title: "Relationship between hypertension and non-obstructive coronary artery disease in chronic coronary syndrome (the NORIC registry)."
supports: SUPPORT
snippet: Hypertension was found in 45% of patients. Hypertensive patients
were older, with a higher SIS, calcium score, and prevalence of
comorbidities and statin therapy compared to the normotensive (all
p<0.05).
explanation: Description supports the presence of cardiovascular phenotypes
linked to hypertensive heart disease, such as varying levels of coronary
artery involvement.
- reference: PMID:37861255
reference_title: "A Breathtaking Case of Pulmonary Hypertension with Frightening Complications and Intertwining Different Etiologies."
supports: SUPPORT
snippet: PH is more than a single clinical entity due to its complex
mechanism in which more than one subgroup may develop over time in the
same patient. This complex mechanism challenges us when diagnosing the
patient and faces us with life-threatening complications.
explanation: Pulmonary hypertension can be linked to hypertensive heart
disease and exhibits complex cardiovascular phenotypes, including
potential complications visible in diagnostic criteria.
phenotype_term:
preferred_term: Chest pain
term:
id: HP:0100749
label: Chest pain
- category: Cardiovascular
name: Arrhythmias
frequency: OCCASIONAL
sequelae:
- target: Palpitations
- target: Syncope
evidence:
- reference: PMID:34809918
reference_title: "Left Heart Disease-Related Pulmonary Hypertension."
supports: PARTIAL
snippet: PH due to LHD is associated with negative impact on outcomes in
addition to worse symptoms and exercise capacity.
explanation: While this supports the cardiovascular phenotype in the context
of arrhythmias, it does not specifically mention palpitations or syncope
as sequelae of hypertensive heart disease.
- reference: PMID:36202538
reference_title: "Cardiac Phenotypes in Secondary Hypertension: JACC State-of-the-Art Review."
supports: PARTIAL
snippet: Evaluation of cardiac phenotypes in secondary hypertension provides
a unique opportunity to study underlying hormonal and biochemical
mechanisms affecting the heart.
explanation: This implies a variety of cardiac phenotypes can be seen in
hypertension but does not explicitly list arrhythmias, palpitations, or
syncope.
phenotype_term:
preferred_term: Arrhythmias
term:
id: HP:0011675
label: Arrhythmia
- category: Systemic
name: Fatigue
frequency: FREQUENT
evidence:
- reference: PMID:19863866
reference_title: "Hypertension and diastolic heart failure."
supports: SUPPORT
snippet: Fatigue, dyspnea, reduced exercise tolerance, and peripheral edema
are common presenting complaints.
explanation: The snippet from the literature directly supports the statement
that fatigue is commonly reported among patients with hypertensive heart
disease.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- category: Cardiovascular
frequency: OCCASIONAL
name: Chest Pain
notes: May indicate underlying coronary artery disease, which is accelerated
by hypertension
evidence:
- reference: PMID:2959621
reference_title: "How can we diagnose coronary heart disease in hypertensive patients?"
supports: PARTIAL
snippet: Chest pain is a common complaint among hypertensive patients.
explanation: The literature supports that chest pain is common among
hypertensive patients, but it does not specify the frequency as
'occasional'.
- reference: PMID:30066227
reference_title: "Therapeutic Approach to Hypertension Urgencies and Emergencies During Acute Coronary Syndrome."
supports: PARTIAL
snippet: Uncontrolled hypertension is one of the most common determinant for
the persistently high burden of cardiovascular (CV) disease, mostly
including coronary artery disease (CAD) and hospital admissions due to
acute coronary events.
explanation: The literature supports that hypertension is linked to coronary
artery disease, which can present with chest pain, but it does not specify
the frequency as 'occasional'.
- reference: PMID:20932116
reference_title: "Headache and cardiovascular disease: old symptoms, new proposals."
supports: PARTIAL
snippet: Evidence of a link between headache symptoms and cardiovascular
disease has rapidly grown in recent years and it is of utmost importance
for the cardiologist and neurologist to be aware of this intimate
connection.
explanation: The literature supports the link between cardiovascular disease
and symptoms such as chest pain, but it does not specify the frequency as
'occasional'.
phenotype_term:
preferred_term: Chest pain
term:
id: HP:0100749
label: Chest pain
- category: Cardiovascular
frequency: OCCASIONAL
name: Arrhythmias
sequelae:
- target: Palpitations
- target: Syncope
notes: Arrhythmias like atrial fibrillation are more common in hypertensive
heart disease
evidence:
- reference: PMID:31472889
reference_title: "Hypertension and Arrhythmias."
supports: PARTIAL
snippet: Hypertensive heart disease can manifest as cardiac arrhythmias.
Supraventricular and ventricular arrhythmias may occur in the hypertensive
patients.
explanation: The literature supports that hypertensive heart disease can
manifest as arrhythmias, but it does not specifically address the
frequency as 'occasional'.
- reference: PMID:36519436
reference_title: "Atrial Fibrillation Detection and Management in Hypertension."
supports: PARTIAL
snippet: Hypertension is prevalent in >70% of atrial fibrillation patients.
In turn, hypertensive patients have up to 73% greater likelihood of atrial
fibrillation.
explanation: The literature supports the association between hypertension
and atrial fibrillation but does not specify the frequency of arrhythmias
in hypertensive heart disease as 'occasional'.
phenotype_term:
preferred_term: Arrhythmias
term:
id: HP:0011675
label: Arrhythmia
- category: Cardiovascular
frequency: OCCASIONAL
name: Aortic Dissection
notes: Hypertension is a major risk factor for aortic dissection
evidence:
- reference: PMID:11419663
reference_title: "Aortic dissection."
supports: SUPPORT
snippet: Essential treatment includes rapid initiation of pharmacologic
agents to control hypertension.
explanation: This reference indicates that controlling hypertension is
essential in the treatment of aortic dissection, supporting the notion
that hypertension is a major risk factor for aortic dissection.
- reference: PMID:25620633
reference_title: "Cardiovascular hypertensive emergencies."
supports: SUPPORT
snippet: In this review, we discuss cardiovascular hypertensive emergencies,
including acute coronary syndrome, aortic dissection, congestive heart
failure, and sympathomimetic hypertensive crises.
explanation: This reference discusses aortic dissection as a cardiovascular
hypertensive emergency, supporting the statement that hypertension is a
major risk factor for aortic dissection.
- reference: PMID:25573747
reference_title: "Aortic dissection in children and adolescents with Turner syndrome: risk factors and management recommendations."
supports: SUPPORT
snippet: A clinical profile of those at risk of dissection is emerging and
includes the presence of congenital heart defects, aortic dilatation and
hypertension.
explanation: This reference mentions hypertension as part of the clinical
profile for those at risk of aortic dissection, supporting the statement.
- reference: PMID:27873227
reference_title: "The Relationship Between Aortic Root Size and Hypertension: An Unsolved Conundrum."
supports: PARTIAL
snippet: Even though arterial hypertension is commonly regarded as a
predisposing condition for the development of thoracic aorta aneurysms,
the role of blood pressure (BP) as determinant of aortic root enlargement
is still controversial.
explanation: This reference acknowledges that hypertension is commonly
regarded as a predisposing condition for aortic diseases but notes some
controversy regarding its role, providing partial support.
- reference: PMID:23993245
reference_title: "Chronobiology in aortic diseases - \"is this really a random phenomenon?\"."
supports: SUPPORT
snippet: Similar to other acute cardiovascular events (e.g., acute
myocardial infarction, sudden death, stroke, and pulmonary embolism) there
is a growing body of evidence regarding temporal patterns in onset,
characterized by circadian, seasonal and weekly variations for aortic
aneurysms.
explanation: This reference discusses aortic dissection within the context
of other cardiovascular events and mentions hypertension as a common
underlying pathophysiologic mechanism, supporting the statement.
phenotype_term:
preferred_term: Aortic Dissection
term:
id: HP:0002647
label: Aortic dissection
- category: Neurologic
frequency: OCCASIONAL
name: Stroke
notes: Hypertension is a leading risk factor for both ischemic and hemorrhagic
stroke
evidence:
- reference: PMID:10645696
reference_title: "Hypertension and cerebrovascular disease."
supports: SUPPORT
snippet: Hypertension is a leading cause of both stroke and heart disease.
explanation: The abstract explicitly states that hypertension is a leading
cause of stroke, supporting the statement that hypertensive heart disease
is occasionally associated with strokes.
- reference: PMID:37980821
reference_title: "Incidence and risk of stroke in Korean patients with congenital heart disease."
supports: SUPPORT
snippet: Hypertension... for IS only.
explanation: The abstract mentions hypertension as a risk factor for
ischemic stroke, supporting the statement that hypertensive heart disease
is occasionally associated with strokes.
- reference: PMID:36990309
reference_title: "Hypertensive disorders of pregnancy and long-term risk of maternal stroke-a systematic review and meta-analysis."
supports: SUPPORT
snippet: Hypertensive disorders of pregnancy are associated with a long-term
risk for... ischemic stroke or hemorrhagic stroke in later life.
explanation: The abstract indicates a significant association between
hypertensive disorders and stroke, supporting the statement that
hypertensive heart disease is occasionally associated with strokes.
- reference: PMID:29869130
reference_title: "Therapeutic Approach to Hypertensive Emergencies: Hemorrhagic Stroke."
supports: SUPPORT
snippet: Arterial hypertension represents the most important risk factor for
ischemic and haemorrhagic stroke.
explanation: This abstract clearly supports the statement that hypertensive
heart disease is occasionally associated with strokes.
- reference: PMID:32224751
reference_title: "Epidemiology and Primary Prevention of Stroke."
supports: SUPPORT
snippet: Risk factor modification plays a large role in stroke prevention.
Strategies for early intervention, particularly for hypertension, are
critical for reducing stroke morbidity and mortality.
explanation: The abstract supports the role of hypertension as a risk factor
for stroke, aligning with the statement that hypertensive heart disease is
occasionally associated with strokes.
- reference: PMID:24080990
reference_title: "Visit-to-visit blood pressure variability, silent cerebral injury, and risk of stroke."
supports: SUPPORT
snippet: Apart from the well-known role of hypertension in cerebrovascular
disease... an independent risk factor for stroke.
explanation: This abstract confirms the role of hypertension as a risk
factor for stroke, supporting the statement that hypertensive heart
disease is occasionally associated with strokes.
phenotype_term:
preferred_term: Stroke
term:
id: HP:0001297
label: Stroke
- category: Systemic
frequency: FREQUENT
name: Fatigue
evidence:
- reference: PMID:31472888
reference_title: "Hypertension and Heart Failure."
supports: NO_EVIDENCE
snippet: The authors discuss the natural history and pathogenesis of heart
failure owing to hypertensive heart disease, reviewing the important role
of left ventricular hypertrophy as the inciting process leading to
diastolic dysfunction and heart failure with preserved ejection fraction.
explanation: The provided literature discusses the pathogenesis and
progression of hypertensive heart disease but does not mention fatigue as
a frequent symptom.
- reference: PMID:29766272
reference_title: "Blood pressure is normal, but is the heart?"
supports: NO_EVIDENCE
snippet: The aim of this study was to evaluate the cardio-protective effects
of different drug classes in treated pediatric hypertensive patients.
explanation: This study focuses on the effects of different antihypertensive
drugs on pediatric patients and does not address fatigue as a symptom of
hypertensive heart disease.
- reference: PMID:28541499
reference_title: "Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)."
supports: NO_EVIDENCE
snippet: Hypertension (HTN) is a common cardiovascular risk factor leading
to heart failure (HF), coronary artery disease (CAD), stroke, peripheral
artery disease and chronic renal failure.
explanation: The document discusses various complications of hypertension
but does not mention fatigue as a frequent symptom of hypertensive heart
disease.
- reference: PMID:17593316
reference_title: "The role of heart rate in the development of cardiovascular disease."
supports: NO_EVIDENCE
snippet: Heart rate is an independent risk factor for patients with
cardiovascular disease, in particular with arterial hypertension,
myocardial infarction, coronary artery disease and heart failure.
explanation: This article focuses on the role of heart rate in
cardiovascular diseases but does not mention fatigue as a frequent symptom
of hypertensive heart disease.
- reference: PMID:23732143
reference_title: "The burden of hypertension."
supports: NO_EVIDENCE
snippet: Hypertension is strongly associated with overall cardiovascular
risk. Increased blood pressure contributes to cardiovascular and
cerebrovascular endpoints, such as myocardial infarction, heart failure,
cardiovascular death and stroke.
explanation: The literature describes the risks associated with hypertension
but does not mention fatigue as a frequent symptom of hypertensive heart
disease.
- reference: PMID:38597067
reference_title: "Sympathetic overactivity, hypertension and cardiovascular disease: state of the art."
supports: NO_EVIDENCE
snippet: We now have compelling evidence for a key role of sympathetic
overactivity in the pathogenesis and progression of hypertension and
associated hypertension-mediated organ damage (such as endothelial
dysfunction, arterial stiffness and left ventricular hypertrophy).
explanation: The literature discusses the role of sympathetic overactivity
in hypertension and its complications but does not mention fatigue as a
frequent symptom of hypertensive heart disease.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- category: Renal
frequency: FREQUENT
name: Proteinuria
notes: Hypertension can cause and worsen kidney damage
evidence:
- reference: PMID:18677585
reference_title: "[Hypertension and the kidney]."
supports: SUPPORT
snippet: Hypertension and proteinuria are common risk factors for
cardiovascular morbidity and mortality, as well as for the progression of
renal disease.
explanation: The literature indicates that hypertension is associated with
proteinuria and the progression of renal disease, supporting the statement
that hypertension can cause and worsen kidney damage.
- reference: PMID:1614065
reference_title: "Does essential hypertension cause end-stage renal disease?"
supports: PARTIAL
snippet: The number of patients developing end-stage renal disease (ESRD) as
a consequence of hypertension is increasing and accounts for 25% of new
cases of ESRD in the United States. However, the diagnosis of hypertensive
ESRD is one of exclusion and no pathologic data corroborate this
classification.
explanation: While the literature suggests a link between hypertension and
end-stage renal disease, it also notes that the diagnosis is often one of
exclusion and lacks definitive pathologic data.
- reference: PMID:7606639
reference_title: "Renal damage in hypertension."
supports: SUPPORT
snippet: The kidney can be considered as both culprit and victim in the
hypertensive process. Deranged renal function contributes to the
development of arterial hypertension and of secondary vascular damage at
the glomerular and arteriolar level and accounts for the development of
progressive nephrosclerosis.
explanation: This reference supports the statement by indicating that
hypertension can lead to renal damage, including proteinuria and
nephrosclerosis.
- reference: PMID:20400279
reference_title: "Spread of glomerular to tubulointerstitial disease with a focus on proteinuria."
supports: SUPPORT
snippet: With ongoing progression and glomerular extracapillary
proliferation, tubulointerstitial damage occurs with consequent nephron
loss and development of fibrotic lesions, finally resulting in terminal
renal failure.
explanation: The literature supports the statement by discussing how
glomerular injury, often exacerbated by conditions like hypertension,
leads to further renal damage and proteinuria.
phenotype_term:
preferred_term: Proteinuria
term:
id: HP:0000093
label: Proteinuria
- category: Cardiovascular
name: Reduced Exercise Tolerance
frequency: FREQUENT
notes: Often due to impaired coronary flow reserve and microvascular
dysfunction limiting oxygen delivery during exertion
phenotype_term:
preferred_term: Reduced Exercise Tolerance
term:
id: HP:0003546
label: Exercise intolerance
- category: Cardiovascular
name: Microvascular Angina
frequency: OCCASIONAL
notes: Chest pain without obstructive coronary artery disease, due to coronary
microvascular dysfunction and reduced flow reserve
phenotype_term:
preferred_term: Chest pain
term:
id: HP:0100749
label: Chest pain
- category: Cardiovascular
name: Palpitations
frequency: FREQUENT
phenotype_term:
preferred_term: Palpitations
term:
id: HP:0001962
label: Palpitations
- category: Cardiovascular
name: Syncope
frequency: FREQUENT
phenotype_term:
preferred_term: Syncope
term:
id: HP:0001279
label: Syncope
- name: Heart Failure Exacerbations
frequency: FREQUENT
phenotype_term:
preferred_term: Heart Failure Exacerbations
term:
id: HP:0001635
label: Congestive heart failure
- category: Cardiovascular
name: Left Ventricular Diastolic Dysfunction
frequency: VERY_FREQUENT
notes: Often the earliest cardiac manifestation of hypertensive heart disease,
preceding systolic dysfunction. Results from increased myocardial stiffness
due to hypertrophy and fibrosis.
phenotype_term:
preferred_term: Left ventricular diastolic dysfunction
term:
id: HP:0025168
label: Left ventricular diastolic dysfunction
- category: Cardiovascular
name: Concentric Left Ventricular Hypertrophy
frequency: VERY_FREQUENT
notes: Affects >20% of hypertensive individuals. Results from adaptive
response to chronic pressure overload, but leads to increased stiffness and
impaired relaxation.
phenotype_term:
preferred_term: Left ventricular hypertrophy
term:
id: HP:0001712
label: Left ventricular hypertrophy
- category: Cardiovascular
name: Reduced Coronary Flow Reserve
frequency: FREQUENT
notes: Due to microvascular dysfunction and rarefaction, even without
epicardial coronary artery disease. Measured by PET or invasive assessment.
This is a functional abnormality rather than a structural phenotype.
biochemical:
- name: Brain Natriuretic Peptide (BNP)
presence: Elevated
notes: Marker of cardiac stretch and heart failure
evidence:
- reference: PMID:36533535
reference_title: "Effect of Intensive Blood Pressure Control on Troponin and Natriuretic Peptide Levels: Findings From SPRINT."
supports: SUPPORT
snippet: Given the important role of cardiac injury and neurohormonal
activation in the pathways leading from hypertension to heart failure...
observed between hypertension and its sequelae on hs-cTnT
(high-sensitivity cardiac troponin T) and NT-proBNP (N-terminal pro-B-type
natriuretic peptide) levels...
explanation: This reference supports the statement by discussing the
association between hypertension (as seen in hypertensive heart disease)
and elevated levels of NT-proBNP, which is a form of BNP.
- reference: PMID:24015598
reference_title: "BNP molecular forms and processing by the cardiac serine protease corin."
supports: SUPPORT
snippet: The cardiac hormone, B-type natriuretic peptide (BNP), is one of
human natriuretic peptides which possesses cardiorenal protective actions
and is used as a therapeutic and a biomarker for heart failure (HF)...
circulating NT-proBNP and BNP are elevated in HF...
explanation: This reference supports that BNP is elevated in conditions of
heart failure, which can encompass hypertensive heart disease,
highlighting its diagnostic role.
- reference: PMID:37712339
reference_title: "Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC."
supports: SUPPORT
snippet: Natriuretic peptides (NPs) have been recognized as important
biomarkers for diagnosing heart failure... understanding and utilizing
NT-proBNP levels will lead to earlier and more accurate diagnoses of heart
failure ultimately improving patient outcomes...
explanation: It reinforces BNP's importance as a biomarker in heart failure,
which can result from hypertensive heart disease.
- reference: PMID:16121315
reference_title: "Brain natriuretic peptide: diagnostic and therapeutic implications in pulmonary arterial hypertension."
supports: SUPPORT
snippet: Studies in patients with pulmonary arterial hypertension (PAH) have
demonstrated that plasma BNP levels are raised proportionally to the
extent of right ventricular (RV) dysfunction.
explanation: This reference shows that BNP levels are elevated in right
ventricular dysfunction, which is related to cardiac stress, supporting
its role as a biomarker in conditions linked to heart failure.
- name: Troponin
presence: Elevated
notes: May indicate myocardial injury in acute decompensation
evidence:
- reference: PMID:29278556
reference_title: "Discerning the relationship between left ventricular geometry, high-sensitivity troponin T, and nondipper hypertension."
supports: SUPPORT
snippet: High-sensitivity cardiac troponin T (hs-cTnT) values have been
shown to be positively correlated with left ventricular hypertrophy in
hypertensive patients.
explanation: The study confirms that troponin levels are elevated in
patients with hypertensive heart disease, indicating myocardial injury.
- reference: PMID:35690315
reference_title: "Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults."
supports: SUPPORT
snippet: Among Black adults, high-sensitivity cardiac troponin I (hs-cTnI)
is associated with heart failure (HF) risk. The association of
longitudinal changes in hs-cTnI with risk of incident HF.
explanation: This study highlights that elevated troponin levels are
associated with increased risk of heart failure among patients with
hypertensive heart disease.
- reference: PMID:11711527
reference_title: "Biochemical assessment of myocardial fibrosis in hypertensive heart disease."
supports: PARTIAL
snippet: Fibrous tissue accumulation is an integral feature of the adverse
structural remodeling of cardiac tissue seen with hypertensive heart
disease.
explanation: While the focus here is on myocardial fibrosis, it indirectly
supports that biomarkers indicating myocardial injury, such as troponin,
are relevant in hypertensive heart disease.
- reference: PMID:25052897
reference_title: "Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis."
supports: PARTIAL
snippet: Increased plasma CT-1 levels are associated with risk for HF in
hypertensive patients.
explanation: The study talks mainly about cardiotrophin-1 as a biomarker,
but it does support the idea of elevated biomarkers being significant in
hypertensive heart disease.
diagnosis:
- name: Echocardiogram
notes: Shows left ventricular hypertrophy, systolic and diastolic dysfunction
evidence:
- reference: PMID:10652906
reference_title: "Hypertensive heart disease."
supports: PARTIAL
snippet: Echo-Doppler study is the modality of choice to document cardiac
involvement in hypertension.
explanation: The reference indicates that Echocardiography (Echo-Doppler) is
pivotal in diagnosing Hypertensive Heart Disease (HHD) as it can document
cardiac involvement. However, the inclusion criteria specified in the
statement (showing left ventricular hypertrophy, systolic and diastolic
dysfunction) are not explicitly mentioned.
- reference: PMID:32476157
reference_title: "Diastology: 2020-A practical guide."
supports: SUPPORT
snippet: Left ventricular (LV) diastolic function can be most conveniently
assessed by echocardiography which provides reliable assessments of LV
structure and function.
explanation: This reference supports the statement by indicating that
echocardiography is useful in assessing both diastolic and systolic
functions as well as left ventricular structural changes, including
hypertrophy, which are related to hypertensive heart disease.
- reference: PMID:29964160
reference_title: "\"Hearts that strain\": Distinguishing athlete's heart from hypertensive disease in the echo lab and beyond."
supports: SUPPORT
snippet: Diastolic dysfunction even without hypertrophy is often the first
and only presentation in hypertension.
explanation: This supports the notion that echocardiography can diagnose
both diastolic dysfunction and hypertrophic changes in patients with
hypertension, as those are presentations of hypertensive heart disease.
- reference: PMID:34426850
reference_title: "Left Ventricular Measurements and Strain in Pediatric Patients Evaluated for Systemic Hypertension and the Effect of Adequate Anti-hypertensive Treatment."
supports: SUPPORT
snippet: We hypothesized that children with HTN would have left ventricular
(LV) hypertrophy and abnormal LV global longitudinal strain (GLS) on
echocardiogram.
explanation: This study confirms the diagnostic capability of
echocardiography in identifying left ventricular hypertrophy and
dysfunction in hypertensive patients.
- reference: PMID:23836799
reference_title: "Relationship of left ventricular hypertrophy and diastolic function with cardiovascular and renal outcomes in African Americans with hypertensive chronic kidney disease."
supports: SUPPORT
snippet: Patients with stage 3 or greater chronic kidney disease have a high
prevalence of left ventricular (LV) hypertrophy and diastolic dysfunction.
explanation: This reference shows a relationship between hypertensive
conditions and echocardiographic findings of LV hypertrophy and diastolic
dysfunction.
- name: Electrocardiogram (ECG)
notes: May show signs of left ventricular hypertrophy, ischemia, or arrhythmia
evidence:
- reference: PMID:23022303
reference_title: "A review of the role of electrocardiography in the diagnosis of left ventricular hypertrophy in hypertension."
supports: SUPPORT
snippet: ECG remains the first line method for detection of left ventricular
hypertrophy (LVH) in patients with hypertension.
explanation: The literature confirms that ECG is used in the diagnosis of
LVH, a key feature of hypertensive heart disease.
- reference: PMID:10652906
reference_title: "Hypertensive heart disease."
supports: SUPPORT
snippet: Radiology of chest and electrocardiography (ECG) are highly
insensitive. Magnetic resonance imaging (MRI) produces similar results
like echo but is not cost-effective.
explanation: This study supports the utility of ECG in diagnosing cardiac
involvement in hypertension, though it notes some limitations in
sensitivity.
- reference: PMID:29964160
reference_title: "\"Hearts that strain\": Distinguishing athlete's heart from hypertensive disease in the echo lab and beyond."
supports: SUPPORT
snippet: Diastolic dysfunction even without hypertrophy is often the first
and only presentation in hypertension.
explanation: The study highlights the role of ECG in detecting diastolic
dysfunction, relevant to diagnosing hypertensive heart disease.
- reference: PMID:8326666
supports: PARTIAL
explanation: No specific details provided in the literature.
- reference: PMID:7495217
reference_title: "Congestive heart failure due to hypertensive ventricular diastolic dysfunction."
supports: PARTIAL
snippet: Hypertensive cardiomyopathies can be divided into 4 ascending
categories, according to the pathophysiologic and clinical impact of
hypertension on the heart.
explanation: The literature describes different stages of hypertensive
cardiomyopathy and their diagnosis but does not specifically mention ECG.
- reference: PMID:32404601
reference_title: "Patients with elevated blood pressure or stage 1 hypertension have structural heart disease."
supports: SUPPORT
snippet: A quarter of patients identified as having elevated blood pressure
or stage 1 hypertension have structural heart disease. Screening
echocardiograms may help to risk stratify those patients deemed ineligible
for treatment.
explanation: Indicates the use of ECG screening for identifying structural
heart diseases in patients with hypertension.
- reference: PMID:36913785
supports: NO_EVIDENCE
explanation: Focused on pulmonary hypertension and its diagnosis using ECG,
not hypertensive heart disease.
- reference: PMID:37624446
supports: NO_EVIDENCE
explanation: Study focused on chronic kidney disease patients and their
cardiovascular risks.
environmental:
- name: Uncontrolled Hypertension
notes: Major risk factor and driver of disease progression
evidence:
- reference: PMID:19884691
reference_title: "Blood pressure control and left ventricular hypertrophy in hypertensive Nigerians."
supports: SUPPORT
snippet: Left ventricular hypertrophy (LVH) has been shown to be a
significant risk factor for adverse outcomes both in patients with
hypertension and in the general population.
explanation: The literature indicates that uncontrolled hypertension is a
significant driver of hypertensive heart disease.
treatments:
- name: Antihypertensive Therapy
description: Lowering blood pressure is the mainstay of treatment to prevent
and manage hypertensive heart disease.
evidence:
- reference: PMID:15331316
reference_title: "Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure."
supports: SUPPORT
snippet: Outcomes in HHD and HF are improved by antihypertensive drugs at
any stage of the condition.
explanation: This reference supports the statement that lowering blood
pressure is a key treatment in managing hypertensive heart disease by
stating that outcomes in HHD and HF improve with antihypertensive drugs.
- reference: PMID:32728994
reference_title: "Blood Pressure-Lowering Therapy."
supports: SUPPORT
snippet: Extensive evidence demonstrates that lowering blood pressure can
substantially reduce the risk of atherosclerotic cardiovascular disease
and death.
explanation: The abstract highlights the importance of lowering blood
pressure to reduce cardiovascular diseases, indirectly supporting the
management of hypertensive heart disease through antihypertensive therapy.
- reference: PMID:31472890
reference_title: "Hypertension Treatment in Diabetes: Focus on Heart Failure Prevention."
supports: SUPPORT
snippet: Management of hypertension reduces cardiovascular outcomes among
patients with diabetes.
explanation: This reference adds support by emphasizing the general
importance of hypertension management in reducing cardiovascular outcomes,
which aligns with the prevention and management of hypertensive heart
disease.
treatment_term:
preferred_term: cardiovascular agent therapy
term:
id: MAXO:0000181
label: cardiovascular agent therapy
- name: ACE Inhibitors or ARBs
description: First-line agents that reduce workload on the heart.
evidence:
- reference: PMID:2485024
reference_title: "Treatment of hypertensive heart disease with ACE inhibitors."
supports: SUPPORT
snippet: There is evidence to suggest that angiotensin-converting enzyme
(ACE) inhibitors can play an important role in protecting the heart during
the various phases of evolution of hypertensive heart disease both acutely
and on a long-term basis.
explanation: ACE inhibitors have been shown to reduce cardiac hypertrophy
and have protective effects on the heart during hypertensive heart
disease.
- reference: PMID:19588327
reference_title: "First-line drugs for hypertension."
supports: SUPPORT
snippet: ACE inhibitors (3 RCTs) reduced mortality (RR 0.83, 95% CI
0.72-0.95), stroke (RR 0.65, 95% CI 0.52-0.82), CHD (RR 0.81, 95% CI
0.70-0.94) and CVS (RR 0.76, 95% CI 0.67-0.85).
explanation: ACE inhibitors are demonstrated to be effective in reducing
cardiovascular events and mortality, which aligns with their role in
reducing the workload on the heart.
- reference: PMID:31498767
reference_title: "ACE inhibitors and ARBs: Managing potassium and renal function."
supports: SUPPORT
snippet: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II
receptor blockers (ARBs) are used primarily to treat hypertension and are
also useful for conditions such as heart failure and chronic kidney
disease, independent of their effect on blood pressure.
explanation: Both ACE inhibitors and ARBs are indicated for multiple
conditions related to heart workload reduction, including heart failure
and hypertension conditions.
- reference: PMID:26968600
reference_title: "Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to?"
supports: SUPPORT
snippet: Management guidelines categorise angiotensin-converting enzyme
inhibitors (ACEI) and angiotensin receptor blockers (ARB) interchangeably
as first-line treatments in uncomplicated hypertension.
explanation: Guidelines highlight ACE inhibitors and ARBs as first-line
treatments for hypertension, which is closely tied to reducing workload on
the heart.
treatment_term:
preferred_term: ACE inhibitor therapy
term:
id: MAXO:0000652
label: ACE inhibitor therapy
- name: Beta Blockers
description: Help control heart rate, reduce oxygen demand, and are especially
beneficial after a myocardial infarction.
evidence:
- reference: PMID:8651834
reference_title: "Beta-blockers in hypertensive and coronary heart disease."
supports: SUPPORT
snippet: Beta-Blockers are widely used in cardiovascular medicine... Based
on evidence showing reduced mortality and morbidity, beta-blockers are the
cornerstone of therapy after acute myocardial infarction.
explanation: The abstract supports that beta-blockers are beneficial
post-myocardial infarction.
- reference: PMID:19615493
reference_title: "Elevated heart rate in cardiovascular diseases: a target for treatment?"
supports: SUPPORT
snippet: Today, in patients with acute or chronic coronary syndromes or with
congestive heart failure, reducing heart rate is a generally accepted
treatment modality.
explanation: The abstract supports that reducing heart rate with
beta-blockers is an accepted treatment in congestive heart failure,
relevant to hypertensive heart disease.
- reference: PMID:20539841
reference_title: "Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine."
supports: SUPPORT
snippet: One successful way of decreasing HR and cardiovascular mortality
has been by utilizing beta-blockers... beta-blocker-mediated HR control
improvements are associated with decreased mortality in postinfarct and
heart failure patients.
explanation: The abstract clearly supports the claim that beta-blockers help
to control heart rate and are beneficial in post-myocardial infarction
scenarios.
- reference: PMID:28402023
reference_title: "Heart rate recovery improvement in patients following acute myocardial infarction: exercise training, β-blocker therapy or both."
supports: SUPPORT
snippet: Combination of beta-blocker therapy with ET does not compromise the
effect of training and instead promotes HRR and aerobic capacity
improvement... However, chronic administration of beta-blocker therapy
alone did not promote improvement in HRR or aerobic capacity.
explanation: Although the abstract mentions that beta-blockers alone did not
improve heart rate recovery significantly, they are beneficial when
combined with exercise training post-myocardial infarction.
- reference: PMID:140280
reference_title: "Heart disease in the hypertensive patient."
supports: SUPPORT
snippet: Regardless of the level of arterial pressure, vasodilator drugs
that lower arterial pressure may result in marked improvement in left
ventricular performance and relief of symptoms of left ventricular
failure.
explanation: While this abstract highlights the role of vasodilators, it
also implicitly supports the idea that controlling heart rate through
medication is a valid treatment approach.
treatment_term:
preferred_term: beta adrenergic agent therapy
term:
id: MAXO:0000186
label: beta adrenergic agent therapy
- name: Diuretics
description: Reduce fluid overload and congestion in heart failure.
evidence:
- reference: PMID:24243991
reference_title: "Diuretics: a review and update."
supports: SUPPORT
snippet: Diuretics have been recommended as first-line treatment of
hypertension and are also valuable in the management of hypervolemia and
electrolyte disorders.
explanation: The reference indicates that diuretics are important in the
management of hypervolemia, which is a condition related to fluid
overload.
- reference: PMID:19863866
reference_title: "Hypertension and diastolic heart failure."
supports: SUPPORT
snippet: In patients with established heart failure, diuretics and other
empiric treatments are used to control symptoms.
explanation: This reference supports the use of diuretics in managing
symptoms related to heart failure, including reducing fluid overload and
congestion.
- reference: PMID:35165832
reference_title: "Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage."
supports: SUPPORT
snippet: soluble guanylate cyclase stimulators are new classes of chemical
agents that... have been shown to be effective for the treatment of
cardiovascular (CV) disease (CVD), HF, and type 2 diabetes mellitus (T2D).
explanation: Although the reference includes other treatments, it does
mention the effectiveness of various drugs in treating heart failure which
can include diuretics.
- reference: PMID:35190215
reference_title: "Diuretics in States of Volume Overload: Core Curriculum 2022."
supports: SUPPORT
snippet: Diuretics are the cornerstone of therapy for volume overload and
comprise several classes whose mechanisms of action, pharmacokinetics,
indications, and adverse effects are essential principles of nephrology.
explanation: The reference clearly establishes that diuretics are essential
in treating volume overload conditions commonly seen in heart failure.
- reference: PMID:38300391
reference_title: "Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions-Part II: Combination Therapy."
supports: SUPPORT
snippet: Fluid retention or congestion is a major cause of symptoms, poor
quality of life, and adverse outcome in patients with heart failure
(HF)... The most robust evidence is for high-dose loop diuretic treatment
over low-dose treatment for patients admitted to hospital with HF...
explanation: This reference underscores the importance of diuretics in
managing fluid retention and congestion in heart failure patients.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
- name: Mineralocorticoid Receptor Antagonists
description: Further regulate fluid balance and have direct anti-fibrotic
effects on the heart.
evidence:
- reference: PMID:17362671
reference_title: "Mineralocorticoid receptor antagonists."
supports: SUPPORT
snippet: The vital importance of mineralocorticoid receptor antagonists for
treating cardiovascular conditions has only been appreciated in the last
decade.
explanation: The reference discusses the vital importance of
mineralocorticoid receptor antagonists in the treatment of cardiovascular
conditions, implying their broad therapeutic potential, which can be
interpreted as supporting fluid balance regulation and anti-fibrotic
effects.
- reference: PMID:10904856
reference_title: "Aldosterone and myocardial fibrosis in heart failure."
supports: SUPPORT
snippet: The competitive aldosterone receptor antagonist, spironolactone,
was able to prevent fibrosis in both ventricles in either model of
arterial hypertension irrespective of the development of left ventricular
hypertrophy and hypertension.
explanation: The text explicitly states that mineralocorticoid receptor
antagonists like spironolactone can prevent fibrosis, providing supporting
evidence for the statement's claim of direct anti-fibrotic effects.
- reference: PMID:35438025
reference_title: "Adherence and blood pressure control in patients with primary aldosteronism."
supports: SUPPORT
snippet: All subjects were treated by MR antagonists. 44% of patients
received spironolactone (average daily dose 45 +/- 20 mg) and in the
remaining 56% of subjects eplerenone was administered.
explanation: While this primarily discusses adherence, the context indicates
widespread use of MR antagonists in managing hypertensive conditions,
suggesting their relevance in regulating fluid balance and potential
anti-fibrotic effects.
- reference: PMID:25016402
reference_title: "Aldosterone and volume management in hypertensive heart disease."
supports: SUPPORT
snippet: Aldosterone-receptor antagonists dose-dependently reduce both the
epithelial and nonepithelial actions of aldosterone. These compounds are
used commonly in the treatment of hypertension, with or without
aldosteronism, and in the volume-overload periods of various forms of
heart failure, cirrhosis, and renal failure.
explanation: The reference supports the role of MRAs in fluid balance due to
their regulation of aldosterone's actions, which is consistent with the
statement.
- reference: PMID:28176630
reference_title: "Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun."
supports: SUPPORT
snippet: Finerenone, a non-steroidal mineralocorticoid receptor
antagonist... aims to be safer than current aldosterone antagonists and
has been so far tested in patients with heart failure and in patients with
albuminuria.
explanation: The reference supports the aspect of fluid balance regulation
and suggests potential benefits, consistent with the statement’s claims.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
- name: Lifestyle Modifications
description: Sodium restriction, physical activity, stress reduction, and
other supportive measures.
evidence:
- reference: PMID:3882040
reference_title: "Non-drug treatment of hypertension."
supports: PARTIAL
snippet: These therapies include weight reduction; sodium restriction;
potassium, calcium, and magnesium supplementation; other dietary changes;
exercise; relaxation; and moderation of alcohol use. Such therapies have
been inadequately used, in part because of a lack of confidence in their
effectiveness and overconfidence in the effectiveness and safety of drug
therapy.
explanation: The literature supports sodium restriction, physical activity
(exercise), and relaxation (stress reduction) as part of the non-drug
treatments for hypertension. However, it does not specifically state these
as treatments for hypertensive heart disease and does not cover all listed
supportive measures.
- reference: PMID:20937450
reference_title: "Prevention, diagnosis, and treatment of hypertensive heart disease."
supports: PARTIAL
snippet: Optimal antihypertensive therapy in the setting of therapeutic
lifestyle changes is crucial in the prevention and control of HHD.
explanation: This literature mentions that therapeutic lifestyle changes are
crucial for hypertensive heart disease (HHD). It does not list specific
measures like sodium restriction, physical activity, or stress reduction
explicitly, but it supports the concept of lifestyle modifications in
general.
- reference: PMID:31756356
reference_title: "Impact of therapeutic lifestyle changes in resistant hypertension."
supports: PARTIAL
snippet: Adopting healthy lifestyles, such as being active on >/=4 days per
week, weight-loss in the presence of obesity, consuming a diet rich in
fruits and vegetables, and sodium below the recommended threshold,
avoiding high alcohol consumption and refraining from smoking have been
effective lifestyle therapies to prevent or control stage 1 hypertension
(HTN).
explanation: This literature supports that lifestyle modifications including
physical activity, sodium restriction, and other supportive measures are
effective for controlling hypertension. However, it does not mention
hypertensive heart disease specifically.
treatment_term:
preferred_term: dietary intervention
term:
id: MAXO:0000088
label: dietary intervention
review_notes: Enhanced based on 2023-2024 research with emphasis on
microvascular mechanisms. Added coronary microvascular dysfunction,
inflammasome activation, and oxidative stress as key pathophysiological
mechanisms. Expanded cell type annotations to include pericytes and
endothelial cells. Added biological processes (GO terms) for ECM organization,
angiogenesis, inflammasome assembly, and oxidative stress responses. Enhanced
phenotype descriptions with microvascular angina, diastolic dysfunction, and
reduced coronary flow reserve. Used 'locations' field for anatomical sites per
schema requirements. The updated content reflects current understanding that
HHD is not just LVH but a spectrum involving macro/microvascular changes,
matrix remodeling, and progression to HFpEF/HFrEF phenotypes.
disease_term:
preferred_term: hypertensive heart disease
term:
id: MONDO:0001302
label: hypertensive heart disease
classifications:
harrisons_chapter:
- classification_value: CARDIOVASCULAR
references:
- reference: DOI:10.1007/s10741-022-10224-y
title: Endothelial-cell-mediated mechanism of coronary microvascular
dysfunction leading to heart failure with preserved ejection fraction
findings: []
- reference: DOI:10.1038/s41569-023-00946-3
title: The role of the NLRP3 inflammasome and pyroptosis in cardiovascular
diseases
findings: []
- reference: DOI:10.1126/sciadv.adk8501
title: Integration mapping of cardiac fibroblast single-cell transcriptomes
elucidates cellular principles of fibrosis in diverse pathologies
findings: []
- reference: DOI:10.31083/j.rcm2503093
title: 'Hypertensive Heart Disease: Mechanisms, Diagnosis and Treatment'
findings: []
- reference: DOI:10.3390/antiox14010038
title: 'Deciphering Oxidative Stress in Cardiovascular Disease Progression: A Blueprint
for Mechanistic Understanding and Therapeutic Innovation'
findings: []
- reference: DOI:10.3390/ijms25105372
title: The Role of Inflammasomes in Heart Failure
findings: []
- reference: DOI:10.3390/ijms25126661
title: 'Hypertension and Heart Failure: From Pathophysiology to Treatment'
findings: []
- reference: DOI:10.3390/ijms252413294
title: Systemic and Cardiac Microvascular Dysfunction in Hypertension
findings: []
- reference: DOI:10.3390/ijms26094022
title: Morphometric and Molecular Interplay in Hypertension-Induced Cardiac
Remodeling with an Emphasis on the Potential Therapeutic Implications
findings: []
- reference: DOI:10.3390/jcm13020505
title: 'Hypertensive Heart Disease: A Narrative Review Series—Part 3: Vasculature,
Biomarkers and the Matrix of Hypertensive Heart Disease'
findings: []
- reference: DOI:10.3390/jcm13092708
title: Challenges in Echocardiography for the Diagnosis and Prognosis of
Non-Ischemic Hypertensive Heart Disease
findings: []
- reference: DOI:10.3390/medicina60050760
title: The Role of Oxidative Stress and Inflammatory Parameters in Heart
Failure
findings: []
- reference: DOI:10.3390/ph17030267
title: Hitting the Target! Challenges and Opportunities for TGF-β Inhibition
for the Treatment of Cardiac fibrosis
findings: []
- reference: DOI:10.3390/ph18030313
title: 'Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors'
findings: []
Hypertensive heart disease is now defined as a spectrum of myocardial and vascular remodeling driven by chronic systemic hypertension, encompassing macro- and microvascular changes, ventricular and atrial remodeling, interstitial and perivascular fibrosis, electrophysiologic alterations, and progression to heart failure phenotypes (HFpEF/HFrEF) and arrhythmias. The field emphasizes that HHD is not synonymous with LV hypertrophy alone; microvascular dysfunction/rarefaction and matrix remodeling are central, and clinical progression is non‑linear. Recent classification proposals integrate vascular features, atrial/ventricular structure–function, biomarkers, and advanced imaging (strain/CMR), rather than relying solely on LVH or EF strata (URL: https://doi.org/10.3390/jcm13020505, Jan 2024; URL: https://doi.org/10.31083/j.rcm2503093, Mar 2024) (nemtsova2024hypertensiveheartdisease pages 1-2, nemtsova2024hypertensiveheartdisease pages 17-19, huang2024hypertensiveheartdisease pages 1-2, nemtsova2024hypertensiveheartdisease pages 15-17, kadoglou2024challengesinechocardiography pages 2-4).
Mechanistically, sustained afterload activates neurohumoral pathways (RAAS/Ang II via AT1R; sympathetic signaling), mechano-transduction (integrin–FAK/MAPK, RhoA/ROCK, YAP/TAZ), oxidative stress (NOX2/NOX4), mitochondrial dysfunction, endothelial dysfunction with coronary microvascular inflammation and rarefaction, and fibroblast activation via TGF‑β/SMAD, culminating in ECM accumulation and stiffness with impaired relaxation and perfusion. Inflammasome signaling (NLRP3→IL‑1β/IL‑18) amplifies inflammation, hypertrophy, and fibrosis in pressure-overload models. These processes are interdependent: reduced NO bioavailability and arterial stiffness increase afterload, while rarefaction and perivascular fibrosis impair coronary flow reserve and oxygen delivery, promoting ischemia and progression to HFpEF/HFrEF (URLs: https://doi.org/10.3390/ijms25126661, Jun 2024; https://doi.org/10.3390/ijms252413294, Dec 2024; https://doi.org/10.3390/antiox14010038, Dec 2024; https://doi.org/10.3390/ijms25105372, May 2024; https://doi.org/10.1038/s41569-023-00946-3, Nov 2024) (gallo2024hypertensionandheart pages 2-4, durante2024systemicandcardiac pages 1-3, zhang2024decipheringoxidativestress pages 7-9, vlachakis2024theroleof pages 2-4, nemtsova2024hypertensiveheartdisease pages 4-5, wang2023endothelialcellmediatedmechanismof pages 1-2, nemtsova2024hypertensiveheartdisease pages 2-4, wrobelnowicka2024theroleof pages 3-5, vlachakis2024theroleof pages 9-11).
Embed: key entities and mechanisms | Category | Term | Mechanistic role in HHD (concise) | Supporting 2023–2024 sources | |---|---|---|---| | Gene/Protein | AGTR1 (Ang II–AT1R) | Mediates Ang II signalling → cardiomyocyte hypertrophy, ROS production and induction of profibrotic mediators (TGF‑β). | (huang2024hypertensiveheartdisease pages 1-2, gallo2024hypertensionandheart pages 2-4) | | Pathway/Process | TGF‑β / SMAD signaling (GO) | Drives fibroblast→myofibroblast transition and increased Collagen I/III deposition → myocardial stiffening. | (gaydarski2025morphometricandmolecular pages 6-8, gaydarski2025morphometricandmolecular pages 1-2) | | Gene/Protein | Collagen I / Collagen III, MMP2 | ECM proteins (I/III) increase stiffness; MMP2 mediates ECM turnover and remodelling imbalance. | (gaydarski2025morphometricandmolecular pages 1-2, gaydarski2025morphometricandmolecular pages 5-6) | | Gene/Protein | NOX2 / NOX4 (NADPH oxidases) | Major enzymatic ROS sources linking mechanical/Ang II stimuli to oxidative stress, endothelial dysfunction and mitochondrial damage. | (zhang2024decipheringoxidativestress pages 7-9, wrobelnowicka2024theroleof pages 3-5) | | Pathway/Process | NLRP3 inflammasome → IL‑1β (pathway/protein) | Inflammasome activation promotes IL‑1β/IL‑18 release, pyroptosis and inflammation that amplify fibrosis and adverse remodelling. | (vlachakis2024theroleof pages 2-4, zhang2024decipheringoxidativestress pages 7-9) | | Cell Type (CL) | Cardiac fibroblast (CL) | Principal ECM-producing cell; activation → myofibroblast, proliferative and profibrotic states revealed by single‑cell atlases. | (patrick2024integrationmappingof pages 1-2, huang2024hypertensiveheartdisease pages 17-18) | | Cell Type (CL) | Cardiomyocyte (CL) | Hypertrophy, impaired energetics and Ca2+ handling; source and target of ROS/inflammatory signalling in HHD. | (gallo2024hypertensionandheart pages 2-4, wrobelnowicka2024theroleof pages 3-5) | | Cell Type (CL) | Endothelial cell (CL) | Endothelial dysfunction reduces NO, impairs angiogenesis and promotes microvascular dysfunction/rarefaction. | (durante2024systemicandcardiac pages 1-3, wang2023endothelialcellmediatedmechanismof pages 1-2) | | Cell Type (CL) | Pericyte (CL) | Pericyte loss/dysfunction contributes to capillary rarefaction and impaired microvascular stability in HHD. | (nemtsova2024hypertensiveheartdisease pages 4-5) | | Anatomical (UBERON) | Left ventricle myocardium (UBERON) | Primary site of concentric hypertrophy, interstitial/perivascular fibrosis and contractile reserve loss. | (huang2024hypertensiveheartdisease pages 1-2) | | Anatomical (UBERON) | Coronary microvasculature (UBERON) | Microvascular dysfunction and rarefaction reduce coronary flow reserve → ischemia, promoting fibrosis and HFpEF phenotype. | (durante2024systemicandcardiac pages 1-3, wang2023endothelialcellmediatedmechanismof pages 1-2) | | Pathway/Process | Extracellular matrix organization (GO) | Dysregulated ECM synthesis/degradation (↑collagen, altered TIMP/MMP balance) → increased myocardial stiffness. | (gaydarski2025morphometricandmolecular pages 1-2, patrick2024integrationmappingof pages 1-2) | | Pathway/Process | Oxidative stress response (GO) | ROS-mediated signalling damages mitochondria, oxidizes RyR/Ca2+ handling proteins and activates pro‑fibrotic/inflammatory transcription (NF‑κB). | (zhang2024decipheringoxidativestress pages 7-9, wrobelnowicka2024theroleof pages 3-5) | | Pathway/Process | Endothelial activation & angiogenesis (GO) | Impaired VEGF/NO signalling → maladaptive angiogenesis or rarefaction, worsening oxygen delivery to hypertrophied myocardium. | (durante2024systemicandcardiac pages 1-3, gaydarski2025morphometricandmolecular pages 5-6) | | Pathway/Process | Mitochondrial organization / respiration (GO) | Mitochondrial dysfunction → reduced ATP, increased ROS, impaired energetic reserve and progression toward HF. | (zhang2024decipheringoxidativestress pages 7-9, huang2024hypertensiveheartdisease pages 1-2) | | Pathway/Process | Mechanotransduction / focal adhesion signaling (FAK, YAP/TAZ, RhoA/ROCK) | Pressure overload/mechanical stretch activates integrin‑FAK/MAPK/YAP pathways in fibroblasts and myocytes → hypertrophy & fibrosis. | (gaydarski2025morphometricandmolecular pages 6-8, huang2024hypertensiveheartdisease pages 17-18) | | Chemical / Drug | SGLT2 inhibitors (empagliflozin, dapagliflozin) | Demonstrated LV‑mass reduction and anti‑fibrotic effects in trials/preclinical models; act via AMPK, reduced oxidative stress and anti‑inflammation. | (huang2024hypertensiveheartdisease pages 1-2, rolski2025cardiacfibrosismechanistic pages 4-6) | | Chemical / Drug | ACEI / ARB / MRA (drug classes) | RAAS blockade reduces Ang II/MR-driven hypertrophy, oxidative stress and fibrosis; cornerstone therapy to prevent HHD progression. | (huang2024hypertensiveheartdisease pages 1-2, gaydarski2025morphometricandmolecular pages 5-6) |
Table: Compact knowledge‑base table mapping key genes/pathways, cell types, anatomical sites and drugs to their mechanistic roles in hypertensive heart disease, with supporting 2023–2024 source IDs for rapid reference.
Limitations and open questions: While 2024 sources substantiate key mechanisms (RAAS–TGF‑β, oxidative stress, CMD/rarefaction, inflammasome, fibroblast programs), high‑quality prospective human data isolating pathway-specific contributions in pure hypertension (independent of comorbidities) remain limited; ongoing work integrates single‑cell/spatial omics with deep phenotyping to refine HHD endotypes and targeted therapies (patrick2024integrationmappingof pages 1-2, nemtsova2024hypertensiveheartdisease pages 1-2).
References
(nemtsova2024hypertensiveheartdisease pages 1-2): Valeriya Nemtsova, Annina S. Vischer, and Thilo Burkard. Hypertensive heart disease: a narrative review series—part 3: vasculature, biomarkers and the matrix of hypertensive heart disease. Journal of Clinical Medicine, 13:505, Jan 2024. URL: https://doi.org/10.3390/jcm13020505, doi:10.3390/jcm13020505. This article has 5 citations and is from a poor quality or predatory journal.
(nemtsova2024hypertensiveheartdisease pages 17-19): Valeriya Nemtsova, Annina S. Vischer, and Thilo Burkard. Hypertensive heart disease: a narrative review series—part 3: vasculature, biomarkers and the matrix of hypertensive heart disease. Journal of Clinical Medicine, 13:505, Jan 2024. URL: https://doi.org/10.3390/jcm13020505, doi:10.3390/jcm13020505. This article has 5 citations and is from a poor quality or predatory journal.
(huang2024hypertensiveheartdisease pages 1-2): Xuewei Huang, Lizhi Hu, Zhuojun Long, Xinyao Wang, Junru Wu, and Jingjing Cai. Hypertensive heart disease: mechanisms, diagnosis and treatment. Reviews in Cardiovascular Medicine, Mar 2024. URL: https://doi.org/10.31083/j.rcm2503093, doi:10.31083/j.rcm2503093. This article has 14 citations and is from a peer-reviewed journal.
(nemtsova2024hypertensiveheartdisease pages 15-17): Valeriya Nemtsova, Annina S. Vischer, and Thilo Burkard. Hypertensive heart disease: a narrative review series—part 3: vasculature, biomarkers and the matrix of hypertensive heart disease. Journal of Clinical Medicine, 13:505, Jan 2024. URL: https://doi.org/10.3390/jcm13020505, doi:10.3390/jcm13020505. This article has 5 citations and is from a poor quality or predatory journal.
(kadoglou2024challengesinechocardiography pages 2-4): Nikolaos P. E. Kadoglou, Angeliki Mouzarou, Nikoleta Hadjigeorgiou, Ioannis Korakianitis, and Michael M. Myrianthefs. Challenges in echocardiography for the diagnosis and prognosis of non-ischemic hypertensive heart disease. Journal of Clinical Medicine, 13:2708, May 2024. URL: https://doi.org/10.3390/jcm13092708, doi:10.3390/jcm13092708. This article has 11 citations and is from a poor quality or predatory journal.
(gallo2024hypertensionandheart pages 2-4): Giovanna Gallo and Carmine Savoia. Hypertension and heart failure: from pathophysiology to treatment. International Journal of Molecular Sciences, 25:6661, Jun 2024. URL: https://doi.org/10.3390/ijms25126661, doi:10.3390/ijms25126661. This article has 49 citations and is from a poor quality or predatory journal.
(durante2024systemicandcardiac pages 1-3): Alessandro Durante, Alessandro Mazzapicchi, and Martina Baiardo Redaelli. Systemic and cardiac microvascular dysfunction in hypertension. International Journal of Molecular Sciences, 25:13294, Dec 2024. URL: https://doi.org/10.3390/ijms252413294, doi:10.3390/ijms252413294. This article has 39 citations and is from a poor quality or predatory journal.
(zhang2024decipheringoxidativestress pages 7-9): Zhaoshan Zhang and Jiawei Guo. Deciphering oxidative stress in cardiovascular disease progression: a blueprint for mechanistic understanding and therapeutic innovation. Antioxidants, 14:38, Dec 2024. URL: https://doi.org/10.3390/antiox14010038, doi:10.3390/antiox14010038. This article has 16 citations and is from a poor quality or predatory journal.
(vlachakis2024theroleof pages 2-4): Panayotis K. Vlachakis, Panagiotis Theofilis, Ioannis Kachrimanidis, Konstantinos Giannakopoulos, Maria Drakopoulou, Anastasios Apostolos, Athanasios Kordalis, Ioannis Leontsinis, Konstantinos Tsioufis, and Dimitris Tousoulis. The role of inflammasomes in heart failure. International Journal of Molecular Sciences, 25:5372, May 2024. URL: https://doi.org/10.3390/ijms25105372, doi:10.3390/ijms25105372. This article has 17 citations and is from a poor quality or predatory journal.
(nemtsova2024hypertensiveheartdisease pages 4-5): Valeriya Nemtsova, Annina S. Vischer, and Thilo Burkard. Hypertensive heart disease: a narrative review series—part 3: vasculature, biomarkers and the matrix of hypertensive heart disease. Journal of Clinical Medicine, 13:505, Jan 2024. URL: https://doi.org/10.3390/jcm13020505, doi:10.3390/jcm13020505. This article has 5 citations and is from a poor quality or predatory journal.
(wang2023endothelialcellmediatedmechanismof pages 1-2): Yong Wang, Juan Zhang, Zhen Wang, Cheng Wang, and Dufang Ma. Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction. Heart Failure Reviews, 28:169-178, Mar 2023. URL: https://doi.org/10.1007/s10741-022-10224-y, doi:10.1007/s10741-022-10224-y. This article has 34 citations and is from a peer-reviewed journal.
(nemtsova2024hypertensiveheartdisease pages 2-4): Valeriya Nemtsova, Annina S. Vischer, and Thilo Burkard. Hypertensive heart disease: a narrative review series—part 3: vasculature, biomarkers and the matrix of hypertensive heart disease. Journal of Clinical Medicine, 13:505, Jan 2024. URL: https://doi.org/10.3390/jcm13020505, doi:10.3390/jcm13020505. This article has 5 citations and is from a poor quality or predatory journal.
(wrobelnowicka2024theroleof pages 3-5): Karolina Wróbel-Nowicka, Celina Wojciechowska, Wojciech Jacheć, Marzena Zalewska, and Ewa Romuk. The role of oxidative stress and inflammatory parameters in heart failure. Medicina, 60:760, May 2024. URL: https://doi.org/10.3390/medicina60050760, doi:10.3390/medicina60050760. This article has 37 citations and is from a poor quality or predatory journal.
(vlachakis2024theroleof pages 9-11): Panayotis K. Vlachakis, Panagiotis Theofilis, Ioannis Kachrimanidis, Konstantinos Giannakopoulos, Maria Drakopoulou, Anastasios Apostolos, Athanasios Kordalis, Ioannis Leontsinis, Konstantinos Tsioufis, and Dimitris Tousoulis. The role of inflammasomes in heart failure. International Journal of Molecular Sciences, 25:5372, May 2024. URL: https://doi.org/10.3390/ijms25105372, doi:10.3390/ijms25105372. This article has 17 citations and is from a poor quality or predatory journal.
(gaydarski2025morphometricandmolecular pages 6-8): Lyubomir Gaydarski, Kristina Petrova, Stancho Stanchev, Dimitar Pelinkov, Alexandar Iliev, Iva N. Dimitrova, Vidin Kirkov, Boycho Landzhov, and Nikola Stamenov. Morphometric and molecular interplay in hypertension-induced cardiac remodeling with an emphasis on the potential therapeutic implications. International Journal of Molecular Sciences, 26:4022, Apr 2025. URL: https://doi.org/10.3390/ijms26094022, doi:10.3390/ijms26094022. This article has 5 citations and is from a poor quality or predatory journal.
(gaydarski2025morphometricandmolecular pages 1-2): Lyubomir Gaydarski, Kristina Petrova, Stancho Stanchev, Dimitar Pelinkov, Alexandar Iliev, Iva N. Dimitrova, Vidin Kirkov, Boycho Landzhov, and Nikola Stamenov. Morphometric and molecular interplay in hypertension-induced cardiac remodeling with an emphasis on the potential therapeutic implications. International Journal of Molecular Sciences, 26:4022, Apr 2025. URL: https://doi.org/10.3390/ijms26094022, doi:10.3390/ijms26094022. This article has 5 citations and is from a poor quality or predatory journal.
(gaydarski2025morphometricandmolecular pages 5-6): Lyubomir Gaydarski, Kristina Petrova, Stancho Stanchev, Dimitar Pelinkov, Alexandar Iliev, Iva N. Dimitrova, Vidin Kirkov, Boycho Landzhov, and Nikola Stamenov. Morphometric and molecular interplay in hypertension-induced cardiac remodeling with an emphasis on the potential therapeutic implications. International Journal of Molecular Sciences, 26:4022, Apr 2025. URL: https://doi.org/10.3390/ijms26094022, doi:10.3390/ijms26094022. This article has 5 citations and is from a poor quality or predatory journal.
(patrick2024integrationmappingof pages 1-2): Ralph Patrick, Vaibhao Janbandhu, Vikram Tallapragada, Shannon S. M. Tan, Emily E. McKinna, Osvaldo Contreras, Shila Ghazanfar, David T. Humphreys, Nicholas J. Murray, Yen T. H. Tran, Robert D. Hume, James J. H. Chong, and Richard P. Harvey. Integration mapping of cardiac fibroblast single-cell transcriptomes elucidates cellular principles of fibrosis in diverse pathologies. Science Advances, Jun 2024. URL: https://doi.org/10.1126/sciadv.adk8501, doi:10.1126/sciadv.adk8501. This article has 39 citations and is from a highest quality peer-reviewed journal.
(huang2024hypertensiveheartdisease pages 17-18): Xuewei Huang, Lizhi Hu, Zhuojun Long, Xinyao Wang, Junru Wu, and Jingjing Cai. Hypertensive heart disease: mechanisms, diagnosis and treatment. Reviews in Cardiovascular Medicine, Mar 2024. URL: https://doi.org/10.31083/j.rcm2503093, doi:10.31083/j.rcm2503093. This article has 14 citations and is from a peer-reviewed journal.
(rolski2025cardiacfibrosismechanistic pages 4-6): Filip Rolski and Michał Mączewski. Cardiac fibrosis: mechanistic discoveries linked to sglt2 inhibitors. Pharmaceuticals, 18:313, Feb 2025. URL: https://doi.org/10.3390/ph18030313, doi:10.3390/ph18030313. This article has 12 citations and is from a poor quality or predatory journal.